Objectives:The current treatment options and therapeutic targets for triple-negative breast cancer(TNBC),an aggressive subtype of breast cancer(BrCA),are limited.This study aimed to identify novel biomarkers and trans...Objectives:The current treatment options and therapeutic targets for triple-negative breast cancer(TNBC),an aggressive subtype of breast cancer(BrCA),are limited.This study aimed to identify novel biomarkers and transcriptional regulatory networks(TRN)inherent in TNBC samples.Methods:We analyzed pan-cancer BrCA datasets from The Cancer Genome Atlas(TCGA)to compare triple-positive breast cancer(TPBC)with TNBC.TRN algorithms and virtual inference of protein-enriched regulon(VIPER)were used to identify master regulators and their target genes.Utilizing TNBC cells(MDA-MB-231 and MDA-MB-468),we validated the relationship of nuclear factor erythroid 2-like 3(NFE2L3)and basic helix-loop-helix family member E 40(BHLHE40)by performing a luciferase assay.The expression levels of these targets were measured after transfections with plasmid and siRNA via qRT-PCR and western blots.The effect of these genes on cell proliferation and migration was studied using phenotypic assays.Results:Using computational approaches,we identified NFE2L3 as a master regulator with BHLHE40 as its target gene.NFE2L3 protein binds to the promoter region of BHLHE40 and regulates its transcriptional activity.Additionally,silencing and overexpressing NFE2L3 and BHLHE40 in TNBC cell lines MDA-MB-231 and MDA-MB-468 showed that NFE2L3 directly regulates BHLHE40 at both transcriptional and translational levels.We found that BHLHE40 requires NFE2L3 for cell proliferation and migration in TNBC.Conclusion:These findings underscore the significance of NFE2L3 and BHLHE40 in TNBC,highlighting NFE2L3’s role in regulating the oncogenic activity of BHLHE40 in TNBC cells.展开更多
目的探索转录因子(NF-E2)相关因子3(NFE2L3)在直肠癌(RC)患者中的表达水平及其与临床预后指标的相关性。方法应用癌症相关数据库GEPIA和Oncomine 中NFE2L3基因的表达水平和预后行生物信息预测;回顾性分析66对RC与配对癌旁组织,行免疫组...目的探索转录因子(NF-E2)相关因子3(NFE2L3)在直肠癌(RC)患者中的表达水平及其与临床预后指标的相关性。方法应用癌症相关数据库GEPIA和Oncomine 中NFE2L3基因的表达水平和预后行生物信息预测;回顾性分析66对RC与配对癌旁组织,行免疫组化的方法检测NFE2L3基因蛋白表达;而后通过Kaplan-Meier单因素和Cox多因素分析研究NFE2L3表达水平与RC患者预后的关系。结果 GEPIA和Oncomine数据库均预测到NFE2L3基因mRNA水平在RC组织中显著高于正常组织( P <0.05),GEPIA数据库显示NFE2L3基因高表达的RC患者临床预后优于低表达者( P =0.041),且该结果与免疫组化结果相一致,RC组织中NFE2L3蛋白高表达( P <0.001),且临床预后优于低表达者( P =0.009)。多因素及单因素生存分析结果提示:NFE2L3蛋白表达水平是RC患者预后的独立预测因子。结论 NFE2L3基因在RC中高表达,可以作为预测RC患者预后良好的独立预测因子,有望成为未来RC患者治疗的新靶点。展开更多
文摘Objectives:The current treatment options and therapeutic targets for triple-negative breast cancer(TNBC),an aggressive subtype of breast cancer(BrCA),are limited.This study aimed to identify novel biomarkers and transcriptional regulatory networks(TRN)inherent in TNBC samples.Methods:We analyzed pan-cancer BrCA datasets from The Cancer Genome Atlas(TCGA)to compare triple-positive breast cancer(TPBC)with TNBC.TRN algorithms and virtual inference of protein-enriched regulon(VIPER)were used to identify master regulators and their target genes.Utilizing TNBC cells(MDA-MB-231 and MDA-MB-468),we validated the relationship of nuclear factor erythroid 2-like 3(NFE2L3)and basic helix-loop-helix family member E 40(BHLHE40)by performing a luciferase assay.The expression levels of these targets were measured after transfections with plasmid and siRNA via qRT-PCR and western blots.The effect of these genes on cell proliferation and migration was studied using phenotypic assays.Results:Using computational approaches,we identified NFE2L3 as a master regulator with BHLHE40 as its target gene.NFE2L3 protein binds to the promoter region of BHLHE40 and regulates its transcriptional activity.Additionally,silencing and overexpressing NFE2L3 and BHLHE40 in TNBC cell lines MDA-MB-231 and MDA-MB-468 showed that NFE2L3 directly regulates BHLHE40 at both transcriptional and translational levels.We found that BHLHE40 requires NFE2L3 for cell proliferation and migration in TNBC.Conclusion:These findings underscore the significance of NFE2L3 and BHLHE40 in TNBC,highlighting NFE2L3’s role in regulating the oncogenic activity of BHLHE40 in TNBC cells.
文摘目的探索转录因子(NF-E2)相关因子3(NFE2L3)在直肠癌(RC)患者中的表达水平及其与临床预后指标的相关性。方法应用癌症相关数据库GEPIA和Oncomine 中NFE2L3基因的表达水平和预后行生物信息预测;回顾性分析66对RC与配对癌旁组织,行免疫组化的方法检测NFE2L3基因蛋白表达;而后通过Kaplan-Meier单因素和Cox多因素分析研究NFE2L3表达水平与RC患者预后的关系。结果 GEPIA和Oncomine数据库均预测到NFE2L3基因mRNA水平在RC组织中显著高于正常组织( P <0.05),GEPIA数据库显示NFE2L3基因高表达的RC患者临床预后优于低表达者( P =0.041),且该结果与免疫组化结果相一致,RC组织中NFE2L3蛋白高表达( P <0.001),且临床预后优于低表达者( P =0.009)。多因素及单因素生存分析结果提示:NFE2L3蛋白表达水平是RC患者预后的独立预测因子。结论 NFE2L3基因在RC中高表达,可以作为预测RC患者预后良好的独立预测因子,有望成为未来RC患者治疗的新靶点。
